Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

Hedskog, Charlotte
Rodriguez, Lauren
Roychoudhury, Pavitra
Huang, Meei-Li
Jerome, Keith R
Hao, Linhui
Ireton, Renee C
Li, Jiani
Perry, Jason K
Han, Dong
Camus, Gregory
Greninger, Alexander L
Gale, Michael Jr
Porter, Danielle P

Gilead Sciences, Inc, Foster City, California, USA
Gilead Sciences, Inc, Foster City, California, USA
Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Center, Seattle, Washington, USA
Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, USA
Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Center, Seattle, Washington, USA
Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, USA
Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, USA
Gilead Sciences, Inc, Foster City, California, USA
Gilead Sciences, Inc, Foster City, California, USA
Gilead Sciences, Inc, Foster City, California, USA
Gilead Sciences, Inc, Foster City, California, USA
Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Center, Seattle, Washington, USA
Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, Washington, USA
Gilead Sciences, Inc, Foster City, California, USA

Presented in part: Hedskog C, et al, IDWeek 2022, 19–23 October 2022, Washington, DC.

Correspondence: Charlotte Hedskog, PhD, Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA 94404 ([email protected]). Danielle P. Porter, PhD, Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA 94404 ([email protected]).

Received January 27, 2023

Accepted July 17, 2023

Revised August 03, 2023

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [email protected]

Journal of Infectious Diseases 228(9):p 1263-1273, November 01, 2023. | DOI: 10.1093/infdis/jiad270